NUS
Nu Skin Enterprises, Inc.10.51
+0.01+0.1%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Q&A reaffirms with light Prism color
Q&A largely reaffirmed prepared remarks on Prism IO and India, adding modest modeling color without revenue specifics. Management noted 100,000 Prism devices by year-end but demurred on subscription uptake, calling it early; impact back-half weighted. India forecast conservatively due to infrastructure hurdles like local manufacturing. Guidance details highlighted gross margin expansion potential akin to 2025, steady 40% selling expenses, G&A alignment, but 35% tax rate tempers EPS from $1.27. TruFace restage draws positive reception. No big surprises. Investors eye Prism adoption.
Key Stats
Market Cap
512.36MP/E (TTM)
4.80Basic EPS (TTM)
2.19Dividend Yield
0.02%Recent Filings
8-K
8-K
Nu Skin names Clark COO
Nu Skin Enterprises appointed Chayce D. Clark, 43, as Executive Vice President, COO, and Chief Legal Officer effective March 5, 2026, expanding his General Counsel role since 2021 to oversee global sales, product innovation, technology, and operations across 50 markets. His new compensation includes $650,000 base salary, 75% target bonus, and $2.4M 2026 equity award split evenly between RSUs and PRSUs. Clark targets sharper execution amid Prysm iO rollout and India expansion.
10-K
FY2025 results
Nu Skin's FY2025 revenue fell 14% y/y to $1.5B, driven by 10% fewer Customers and 19% fewer Sales Leaders amid macro headwinds, yet Q4 Prysm iO preview kicked off device momentum. Core Nu Skin topline dropped 13%, but gross margins expanded 3.1 points to 77% via portfolio optimization; Rhyz Manufacturing grew 2%, while Other plunged 79% post-Mavely sale. $176M gain from that divestiture flipped net income positive at $160M ($3.18/share), fueling $170M debt paydown to $225M term loan. Q4 stabilized Sales Leaders sequentially. China scrutiny threatens sales force retention.
8-K
Q4 results within guidance
Nu Skin reported Q4 2025 revenue of $370.3 million, down 16.9% year-over-year, and full-year revenue of $1.49 billion, down 14.3%, yet EPS soared to $3.18 from $(2.95) amid cost cuts and a $176 million Mavely sale gain. Sales leaders fell 19% to 30,045, but Prysm iO devices reached 20,000 leaders with 700,000 scans. Earnings grew over 50%. Guides 2026 revenue $1.35-$1.50 billion, targeting year-end growth.
10-Q
Q3 FY2025 results
Nu Skin revenue fell 15% y/y to $364.2M in Q3 ended September 30, 2025, yet operating income rose 19% to $21.6M with gross margins steady at 70.5% amid cost controls. Diluted EPS climbed to $0.34 from $0.17, reconciling to 50.3M shares. YTD revenue dropped 13% to $1.1B but swung to $42.5M operating income versus a $98.5M loss, fueled by a $176.2M Mavely sale gain (closed Jan 2025 for $193.7M net cash) offset by $25.1M BeautyBio impairment and $28.1M equity investment loss in other expense. Cash hit $251.8M with OCF $63.7M less $23.5M capex; debt shrank to $229M term loan (6.26% variable) from repayments, revolver at $0 with covenants met. Debt watchdogs.
IPO
Website
Employees
Sector
Industry
DQWS
Dswiss Inc
0.04+0.00
EL
Estee Lauder Companies, Inc. (T
104.39+3.36
ELF
e.l.f. Beauty, Inc.
78.77+0.17
HNST
The Honest Company, Inc.
2.86+0.05
NATR
Nature's Sunshine Products, Inc
22.38-0.85
PHH
Park Ha Biological Technology C
0.39-0.00
SKIN
The Beauty Health Company
1.41+0.03
SKVI
SKINVISIBLE INC
0.43+0.00
USNA
USANA Health Sciences, Inc.
20.33+0.01
XAGE
Longevity Health Holdings, Inc.
0.44-0.05